Sign In
Buy AYTU
$2.09
-0.0100 (-0.476%)
At Close: Jun 03, 2026
ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors
04:49pm, Monday, 04'th Oct 2021
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
08:01am, Thursday, 30'th Sep 2021
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 202
Recap: Aytu BioPharma Q4 Earnings
07:05am, Wednesday, 29'th Sep 2021
Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what investors need to know about the an
Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript
07:36pm, Monday, 27'th Sep 2021
Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
08:00am, Thursday, 23'rd Sep 2021
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,
Aytu BioPharma to Present at Upcoming September Investor Conferences
08:00am, Tuesday, 07'th Sep 2021
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,
ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, anno
Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options
09:46am, Wednesday, 07'th Jul 2021
Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
08:50am, Monday, 28'th Jun 2021
Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19
Technical Levels To Watch In Aytu BioPharma Stock
04:27pm, Monday, 21'st Jun 2021
Aytu BioPharma Inc. (NASDAQ: AYTU) shares were rallying Monday after retail traders were able to push the stock higher. The stock has traded on above-average volume with 7.6 million shares traded so
What's Next For Aytu BioPharma Stock As It Gaps Up To Resistance?
12:14pm, Tuesday, 08'th Jun 2021
Aytu BioPharma Inc. (NASDAQ: AYTU) shares saw a gap up Tuesday morning as retail traders tried to push the stock higher. The stock saw a sizable premarket move and opened at $6.15, but has since falle
Aytu BioPharma to Present at Upcoming June Investor Conferences
08:01am, Tuesday, 25'th May 2021
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, annou
Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
08:24pm, Monday, 17'th May 2021
Aytu Biopharma, Inc. (AYTU) CEO Joshua Disbrow on Q3 2021 Results - Earnings Call Transcript
Recap: Aytu BioPharma Q3 Earnings
04:48pm, Monday, 17'th May 2021
Shares of Aytu BioPharma (NASDAQ:AYTU) decreased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 186.67% year over year to ($0.43), which misse
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
04:01pm, Monday, 17'th May 2021
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β i
